Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma

Ali, Hamdy; Hameed, Rehab Abdel; Effat, Heba; Ahmed, Emad K.; Atef, Azza A.; Sharawi, Sabry K.; Ali, Mohamed; Elmageed, Zakaria Y. Abd; Wahab, Abdel

doi:10.1016/j.clinre.2017.06.004

Cited by 42 publications

(39 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Separately, 11 studies from eight articles 15,[56][57][58][59][60][61][62] were included in the diagnostic meta-analysis and 14 studies from 13 articles 15,24,29,41,47,51,[63][64][65][66][67][68][69] were included in the prognostic meta-analysis. After screening the titles and abstracts, 476 articles were excluded because they were reviews (n = 18), meta-analyses (n = 5), nonhuman studies (n = 14), or studies irrelevant to our topic (n = 439).…”

Section: The Basic Characteristic Of Meta-analysismentioning

confidence: 99%

Molecular mechanism and role of microRNA‐93 in human cancers: A study based on bioinformatics analysis, meta‐analysis, and quantitative polymerase chain reaction validation

Gao

Deng

Liu

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Introduction Currently, studies have shown that microRNA‐93 (miR‐93) can be an oncogene or a tumor suppressor in different kinds of cancers. The role of miR‐93 in human cancers is inconsistent and the underlying mechanism on the aberrant expression of miR‐93 is complicated. Methods We first conducted gene enrichment analysis to give insight into the prospective mechanism of miR‐93. Second, we performed a meta‐analysis to evaluate the clinical value of miR‐93. Finally, a validation test based on quantitative polymerase chain reaction (qPCR) was performed to further investigate the role of miR‐93 in pan‐cancer. Results Gene Ontology (GO) enrichment analysis results showed that the target genes of miR‐93 were closely related to transcription, and MAPK1, RBBP7 and Smad7 became the hub genes. In the diagnostic meta‐analysis, the overall sensitivity, specificity, and area under the curve were 0.76 (0.64‐0.85), 0.82 (0.64‐0.92), and 0.85 (0.82‐0.88), respectively, which suggested that miR‐93 had excellent performance on the diagnosis for human cancers. In the prognostic meta‐analysis, dysregulated miR‐93 was found to be associated with poor OS in cancer patients. In the qPCR validation test, the serum levels of miR‐93 were upregulated in breast cancer, breast hyperplasia, lung cancer, chronic obstructive pulmonary disease, nasopharyngeal cancer, hepatocellular cancer, gastric ulcer, endometrial cancer, esophageal cancer, laryngeal cancer, and prostate cancer compared with healthy controls. Conclusions miR‐93 could act as an effective diagnostic and prognostic factor for cancer patients. Its clinical value for cancer early diagnosis and survival prediction is promising.

show abstract

Section: The Basic Characteristic Of Meta-analysismentioning

confidence: 99%

Molecular mechanism and role of microRNA‐93 in human cancers: A study based on bioinformatics analysis, meta‐analysis, and quantitative polymerase chain reaction validation

Gao

Deng

Liu

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…The diagnostic accuracy using these miRNAs, as measured by AUC, was 0.665, 0.68, 0.607, 0.534, 0.609, 0.729, 0.69 and 0.677, respectively [120] . Ali et al [121] showed that miR-122, miR-21 and miR-222 had the highest sensitivity and specificity, in discriminating HCC from healthy controls (miR-122: 94.3% and 92.9% respectively; miR-21: 80% and 92.9% respectively, and miR-222: 82.9% and 78.6%, respectively).…”

Section: Circulating Mirnasmentioning

confidence: 99%

“…A positive linear correlation was present between serum ALT and serum miR-122 levels in mouse models of alcoholic liver disease (r = 0.893; P < 0.001) [100] and it was postulated to be a key regulator of alpha-fetoprotein expression and it could influence the aggressiveness of the HCC in an in vitro model [119] . Using panels of miRNAs may provide a high diagnostic accuracy of HCC regardless of the disease status, and it can also differentiate HCC from healthy controls and chronic liver injury [120,121] . These were hsa-miR-206, hsa-miR-141-3p, hsamiR-433-3p, hsa-miR-1228-5p, hsa-miR-199a-5p, hsa-miR-122-5p, hsa-miR-192-5p, and hsa-miR-26a-5p.…”

Section: Circulating Mirnasmentioning

confidence: 99%

Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas¹,

Sánchez‐Torrijos²,

Gil‐Gómez³

et al. 2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second cause of cancer related death due to latent liver disease, late diagnosis and non-available therapeutic treatment. Liver biopsy is still the gold standard in order to know the molecular biology of the tumor, its behaviour and invasive characteristics. Conventional diagnosis methods for HCC detection include imaging and serological tests with low sensitivity and specificity. In this review, we focus on the potential utility of certain serum biomarkers and a new approach, "liquid biopsy", in the management of HCC patients.

show abstract

“…Seventeen studies were further excluded after full-text review, because they were animal studies (n = 1), not designed as diagnostic studies (n = 5), reported exosomal miR-122 expression rather than circulating miR-122 expression (n = 3), evaluated single nucleotide polymorphisms of miR-122 (n = 1), or reported diagnostic efficacies with no available data for miR-122 (n = 7). Finally, 13 studies were included [11][12][13][14][16][17][18][19][20][21][22][23][24].…”

Section: Studies Identified By Databasementioning

confidence: 99%

“…However, due to the small number of studies included, they were unable to evaluate the efficacy of circulating miR-122 for discriminating HCC patients from various control patient populations [15]. Since the publication of their meta-analysis, several additional studies regarding the diagnostic efficacy of miR-122 for HCC have been published [16][17][18][19][20][21][22][23][24]. Therefore, we aimed to quantitatively evaluate the potential diagnostic performance of circulating miR-122 for HCC in an updated meta-analysis.…”

Section: Introductionmentioning

confidence: 99%

Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis

Zhao

Lin

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. Circulating microRNA-122 (miR-122) has been recognized as a marker of hepatocellular carcinoma (HCC). The current meta-analysis was performed to quantitatively evaluate the diagnostic performance of circulating miR-122 for HCC. Methods. Related studies that evaluated the diagnostic performance of circulating miR-122 determined from pathophysiological examination for HCC were obtained by systematic searches of the PubMed and Embase databases. A randomized fixed effects model was applied according to the heterogeneity among studies. The pooled sensitivity, specificity, and area under the summary receiver operating characteristic curve (AUC) were calculated to evaluate the diagnostic accuracy. Publication bias was detected by Deeks' funnel plot asymmetry test. Results. Thirteen studies providing data for 920 HCC patients and 1217 controls were included in the meta-analysis. The pooled sensitivities, specificities, and AUCs of serum miR-122 were 0.76, 0.75, and 0.82, respectively, for discriminating HCC patients from overall controls; 0.85, 0.83, and 0.91, respectively, for discriminating HCC patients from healthy controls; 0.79, 0.82, and 0.87, respectively, for discriminating HCC from HBV or HCV infection; and 0.65, 0.75, and 0.74, respectively, for discriminating HCC from liver cirrhosis or dysplastic nodule formation. No significant publication bias was detected. Conclusions. Serum miR-122 confers moderate efficacy for discriminating HCC patients from healthy controls or patients with HBV or HCV infection, but not for discriminating HCC patients from those with liver cirrhosis or dysplastic nodule formation.

show abstract

Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma

Cited by 42 publications

References 53 publications

Molecular mechanism and role of microRNA‐93 in human cancers: A study based on bioinformatics analysis, meta‐analysis, and quantitative polymerase chain reaction validation

Molecular mechanism and role of microRNA‐93 in human cancers: A study based on bioinformatics analysis, meta‐analysis, and quantitative polymerase chain reaction validation

Performance of different biomarkers for the management of hepatocellular carcinoma

Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis

Contact Info

Product

Resources

About